Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Latest Information Update: 16 May 2025
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 13 May 2025 Planned initiation date to 16 May 2025.
- 04 May 2025 Planned initiation date changed to 8 May 2025.
- 27 Apr 2025 Planned initiation date changed from 30 Apr 2025 to 1 May 2025.